HSINCHU, Taiwan and WUHAN, China, August 16, 2019 -- JHL Biotech has reached a settlement agreement with Genentech to resolve Genentech’s civil claims related to the development of certain biologic... read more →
HSINCHU, Taiwan and WUHAN, China, June 13, 2018 /PRNewswire/ -- JHL Biotech has raised US$106 million in a convertible bond issuance, which closed May 15, 2018. Proceeds raised from the... read more →
HSINCHU, Taiwan and WUHAN, China, February 3, 2018 -- JHL Biotech (TPEx: 6540) announced that the Taipei Exchange (“TPEx”) granted approval on February 2 for the termination of trading of... read more →
HSINCHU, Taiwan and WUHAN, China, January 1, 2018 -- JHL Biotech announced that Rong Chen has been appointed Chief Medical Officer effective January 1. As CMO, Dr. Chen will oversee... read more →
JHL Biotech, Inc. (“JHL”, 6540. TWO) was awarded a top 20 ranking in Deloitte Touche Tohmatsu Limited’s 2017 Asia Technology Fast 500™ list. This annual ranking compares the fastest growing... read more →
Shanghai, China - 5 December 2016 – Sanofi (EURONEXT: SAN and NYSE: SNY), a global healthcare leader and JHL Biotech, Inc. (6540.TWO), a biopharmaceutical company with development and manufacturing facilities... read more →
Singapore and Hsinchu, Taiwan, 14 November 2016 – ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, and JHL Biotech,... read more →
喜康武汉KUBio工厂获得2016卓越设施设计奖 一、武汉神级玩家 - 喜康生物获2016卓越设施设计奖 (more…)
Hsinchu, Taiwan and Wuhan, China, November 1st, 2016 – JHL Biotech (“JHL”, Stock Code: 6540.TWO) has announced that WeiDong Cui, Ph.D. has joined JHL Biotech as Corporate VP of Manufacturing and Technology,... read more →